Carboplatin Hypersensitivity in Relapsed Ovarian Carcinoma: A Therapeutic Challenge

Overview

Journal Indian J Med Paediatr Oncol

Publisher Thieme

Specialty Oncology

Date 2014 Jul 10

PMID 25006278

Citations 4

Authors

Avinash Pandey

Bharat Bhosale

Vimal Pandita

Ashish Singh

Joydeep Ghosh

Jaya Ghosh

Jyoti Bajpai

Affiliations

Soon will be listed here.

Abstract

Carboplatin and paclitaxel as doublet are the standard therapeutic option for advanced stage ovarian carcinoma in the first line as well as relapse. Carboplatin with its better toxicity profile has replaced cisplatin as the first line drug. However, increase in incidence of carboplatin hypersensitivity is alarming. Severity of carboplatin hypersensitivity varies from a mild rash to life-threatening reactions. With an increase in the number of cycles the risk of hypersensitivity reactions increase, which jeopardizes the use of this highly effective drug in a significant proportion of patients. Prompt diagnosis and rapid therapeutic rescue are the key in severe life-threatening reactions. Managing patients with carboplatin hypersensitivity and planning subsequent therapy is thus a therapeutic challenge.

Citing Articles

Allergy in Cancer Care: Antineoplastic Therapy-Induced Hypersensitivity Reactions.

Galateanu B, Puscasu A, Tircol S, Tanase B, Hudita A, Negrei C Int J Mol Sci. 2023; 24(4).

PMID: 36835299 PMC: 9961679. DOI: 10.3390/ijms24043886.

Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives.

Forgie B, Prakash R, Telleria C Int J Mol Sci. 2022; 23(23).

PMID: 36499737 PMC: 9793759. DOI: 10.3390/ijms232315410.

Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study.

Pornwattanakrilert W, Suprasert P Asian Pac J Cancer Prev. 2017; 18(2):425-430.

PMID: 28345825 PMC: 5454738. DOI: 10.22034/APJCP.2017.18.2.425.

Idiosyncratic Reaction with Cytokine Storm Associated with Oxaliplatin.

Dembla V Cureus. 2016; 8(5):e615.

PMID: 27335720 PMC: 4914067. DOI: 10.7759/cureus.615.

References

Schwartz J, Bandera C, Bradley A, Brard L, Legare R, Granai C . Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol. 2006; 105(1):81-3. DOI: 10.1016/j.ygyno.2006.10.047. View

Rose P, Fusco N, Fluellen L, Rodriguez M . Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 1998; 16(4):1494-7. DOI: 10.1200/JCO.1998.16.4.1494. View

Sliesoraitis S, Chikhale P . Carboplatin hypersensitivity. Int J Gynecol Cancer. 2005; 15(1):13-8. DOI: 10.1111/j.1048-891x.2005.14401.x. View

Aabo K, Adams M, Adnitt P, Alberts D, Athanazziou A, Barley V . Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer. 1998; 78(11):1479-87. PMC: 2063202. DOI: 10.1038/bjc.1998.710. View

Zanotti K, Rybicki L, Kennedy A, Belinson J, Webster K, Kulp B . Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001; 19(12):3126-9. DOI: 10.1200/JCO.2001.19.12.3126. View

OCearbhaill R, Zhou Q, Iasonos A, Hensley M, Tew W, Aghajanian C . The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2009; 116(3):326-31. PMC: 4369374. DOI: 10.1016/j.ygyno.2009.10.070. View

Shukunami K, Kurokawa T, Kawakami Y, Kubo M, Kotsuji F . Hypersensitivity reactions to intraperitoneal administration of carboplatin in ovarian cancer: the first report of a case. Gynecol Oncol. 1999; 72(3):431-2. DOI: 10.1006/gyno.1998.5273. View

Robinson J, Singh D, Wharton J, Gershenson D, Wolf J . Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol. 2001; 82(3):550-8. DOI: 10.1006/gyno.2001.6331. View

Callahan M, LaChance J, Stone R, Kelsey J, Rice L, Jazaeri A . Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol. 2007; 197(2):199.e1-4. DOI: 10.1016/j.ajog.2007.04.044. View

10.

Markman M . Hypersensitivity reactions to carboplatin. Gynecol Oncol. 2002; 84(2):353-4. DOI: 10.1006/gyno.2001.6513. View

11.

Markman M, Zanotti K, Kulp B, Peterson G, Markman M . Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity. Gynecol Oncol. 2003; 89(3):514-6. DOI: 10.1016/s0090-8258(03)00155-0. View

12.

Dizon D, Sabbatini P, Aghajanian C, Hensley M, Spriggs D . Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002; 84(3):378-82. DOI: 10.1006/gyno.2001.6519. View

13.

Rose P, Fusco N, Smrekar M, Mossbruger K, Rodriguez M . Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003; 89(3):429-33. DOI: 10.1016/s0090-8258(03)00178-1. View

14.

McAlpine J, Kelly M, OMalley D, Azodi M, Coombe K, Schwartz P . Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies. Gynecol Oncol. 2006; 103(1):288-92. DOI: 10.1016/j.ygyno.2006.03.007. View

15.

Parmar M, Ledermann J, Colombo N, Bois A, Delaloye J, Kristensen G . Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361(9375):2099-106. DOI: 10.1016/s0140-6736(03)13718-x. View

16.

Ozols R, Bundy B, Greer B, Fowler J, Clarke-Pearson D, Burger R . Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21(17):3194-200. DOI: 10.1200/JCO.2003.02.153. View

17.

Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J . Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003; 21(24):4611-4. DOI: 10.1200/JCO.2003.05.539. View